Shareholder Democracy
Why It MattersHow It Works

Regeneron Pharmaceuticals

REGN · Nasdaq · Health Care

☆ Follow

Shareholder advocacy aimed at Regeneron Pharmaceuticals

Nothing recorded yet. That means no campaign in our database names this company, not that none exists.

What shareholders voted on

From Regeneron Pharmaceuticals’s own filings with the SEC. Support is the share of votes cast for and against, so abstentions and broker non-votes are not counted in it.

2026

ItemKindAsked for bySupportOutcome
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026Say on pay93.3%Passed
Huda Y. Zoghbi, M.DCompany proposal97.4%Passed
David P. Schenkein, M.DCompany proposal96%Passed
Craig B. Thompson, M.DCompany proposal79.3%Passed
Christine A. PoonCompany proposal76.8%Passed
Joseph L. Goldstein, M.DCompany proposal70.1%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026Auditor94.1%Passed

2025

ItemKindAsked for bySupportOutcome
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 29, 2025Say on pay93.3%Passed
Class A Stock Common StockCompany proposal97.4%Passed
George D. Yancopoulos, M.D., Ph.DCompany proposal96.1%Passed
Leonard S. Schleifer, M.D., Ph.DCompany proposal93.7%Passed
Bonnie L. Bassler, Ph.DCompany proposal82.4%Passed
Amend the Company’s Certificate of Incorporation to declassify the board of directorsCompany proposal80.9%Passed
Michael S. Brown, M.DCompany proposal72.7%Passed
Class A StockCompany proposal0%Failed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025Auditor94.6%Passed

2024

ItemKindAsked for bySupportOutcome
The non-binding shareholder proposal requesting simple majority voting requirementsShareholder proposal76.5%Passed
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 25, 2024Say on pay95%Passed
Kathryn Guarini, Ph.DCompany proposal99.7%Passed
N. Anthony Coles, M.DCompany proposal98.3%Passed
David P. Schenkein, M.DCompany proposal95.1%Passed
George L. SingCompany proposal91.5%Passed
Arthur F. RyanCompany proposal72.1%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024Auditor95.5%Passed

2023

ItemKindAsked for bySupportOutcome
The non-binding shareholder proposal requesting report on a process by which access to medicine is considered in matters related to protecting intellectual propertyShareholder proposal9.4%Failed
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy StatementSay on pay87.1%Passed
Craig B. Thompson, M.DCompany proposal99.4%Passed
Huda Y. Zoghbi, M.DCompany proposal96.3%Passed
Christine A. PoonCompany proposal75.3%Passed
Joseph L. Goldstein, M.DCompany proposal70.3%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023Auditor96.3%Passed

2022

ItemKindAsked for bySupportOutcome
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy StatementSay on pay87.8%Passed
Leonard S. Schleifer, M.D., Ph.DCompany proposal98.7%Passed
George D. Yancopoulos, M.D., Ph.DCompany proposal98.2%Passed
Bonnie L. Bassler, Ph.DCompany proposal86.9%Passed
Michael S. Brown, M.DCompany proposal77.4%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022Auditor96.1%Passed

2021

ItemKindAsked for bySupportOutcome
Arthur F. RyanCompany proposal79.7%Passed
N. Anthony Coles, M.DCompany proposal69.9%Passed
Marc Tessier-Lavigne, Ph.DCompany proposal66.8%Passed
George L. SingCompany proposal50.8%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021Auditor96.4%Passed

2020

ItemKindAsked for bySupportOutcome
The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy StatementSay on pay70.2%Passed
N. Anthony Coles, M.DCompany proposal99.5%Passed
P. Roy Vagelos, M.DCompany proposal98.4%Passed
Huda Y. Zoghbi, M.DCompany proposal95.6%Passed
Joseph L. Goldstein, M.DCompany proposal95.1%Passed
Christine A. PoonCompany proposal91.5%Passed
Approve the PlanCompany proposal73.5%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020Auditor98.4%Passed

2019

ItemKindAsked for bySupportOutcome
Leonard S. Schleifer, M.D., Ph.DCompany proposal83.8%Passed
George D. Yancopoulos, M.D., Ph.DCompany proposal83.7%Passed
Bonnie L. Bassler, Ph.DCompany proposal75.4%Passed
Michael S. Brown, M.DCompany proposal70.7%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019Auditor98.3%Passed

2018

ItemKindAsked for bySupportOutcome
Marc Tessier-Lavigne, Ph.DCompany proposal94.8%Passed
Ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018Auditor99.2%Passed
Election of Arthur F. RyanDirector88.8%Passed
Election of George L. SingDirector64%Passed

Proxy statements and vote results

Straight from Regeneron Pharmaceuticals’s own SEC filings. The proxy statement lists what shareholders were asked to vote on; the 8-K certifies how the vote went.

YearFilingFiled
2026Vote results2026-06-17
2026Proxy statement2026-04-24
2025Vote results2025-06-18
2025Proxy statement2025-04-29
2024Vote results2024-06-20
2024Proxy statement2024-04-25
2023Vote results2023-06-14
2023Proxy statement2023-04-21
2022Vote results2022-06-15
2022Proxy statement2022-04-21
2021Vote results2021-06-16
2021Proxy statement2021-04-23
2020Vote results2020-06-16
2020Proxy statement2020-04-24
2019Vote results2019-06-19
2019Proxy statement2019-04-26
2018Vote results2018-06-13
2018Proxy statement2018-04-23

Do you represent Regeneron Pharmaceuticals? Claim this profile to respond to the campaigns listed here.

← All companies